Compare EXFY & RXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXFY | RXST |
|---|---|---|
| Founded | 2008 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 217.0M | 197.6M |
| IPO Year | 2021 | 2021 |
| Metric | EXFY | RXST |
|---|---|---|
| Price | $2.45 | $4.58 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 3 | 10 |
| Target Price | $2.83 | ★ $7.57 |
| AVG Volume (30 Days) | 455.0K | ★ 728.6K |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $142,101,000.00 | N/A |
| Revenue This Year | N/A | $9.36 |
| Revenue Next Year | $0.15 | $1.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.06 | N/A |
| 52 Week Low | $0.69 | $4.45 |
| 52 Week High | $2.81 | $13.22 |
| Indicator | EXFY | RXST |
|---|---|---|
| Relative Strength Index (RSI) | 57.97 | 33.15 |
| Support Level | $2.05 | N/A |
| Resistance Level | $2.80 | $4.99 |
| Average True Range (ATR) | 0.11 | 0.21 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 95.18 | 25.69 |
Expensify Inc is a cloud-based expense management software platform that helps various businesses simplify the way to manage money. It is used to scan and reimburse receipts from flights, hotels, coffee shops, office supplies and ride shares. People use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay and travel booking in one app. Small and medium-sized businesses (SMBs) are the cornerstone of the global economy, making up almost all businesses and the majority of employment in Organization for Economic Co-operation and Development (OECD) member countries.
RxSight Inc is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture, and sale of light adjustable lenses and related capital equipment.